

MEDICAL POLICY

POLICY TITLE	CHROMOSOMAL MICROARRAY TESTING FOR THE EVALUATION OF PREGNANCY LOSS
POLICY NUMBER	MP 7.028

CLINICAL BENEFIT	<input type="checkbox"/> MINIMIZE SAFETY RISK OR CONCERN. <input type="checkbox"/> MINIMIZE HARMFUL OR INEFFECTIVE INTERVENTIONS. <input type="checkbox"/> ASSURE APPROPRIATE LEVEL OF CARE. <input type="checkbox"/> ASSURE APPROPRIATE DURATION OF SERVICE FOR INTERVENTIONS. <input checked="" type="checkbox"/> ASSURE THAT RECOMMENDED MEDICAL PREREQUISITES HAVE BEEN MET. <input type="checkbox"/> ASSURE APPROPRIATE SITE OF TREATMENT OR SERVICE.
Effective Date:	1/1/2025

[POLICY RATIONALE](#)
[DISCLAIMER](#)
[POLICY HISTORY](#)

[PRODUCT VARIATIONS](#)
[DEFINITIONS](#)
[CODING INFORMATION](#)

[DESCRIPTION/BACKGROUND](#)
[BENEFIT VARIATIONS](#)
[REFERENCES](#)

I. POLICY

Chromosomal microarray testing of fetal tissue may be considered **medically necessary** for the evaluation of pregnancy loss in individuals with indications for genetic analysis of the embryo or fetus. Genetic testing may be considered **medically necessary** (if desired by parents) for the following:

- In cases of pregnancy loss at 20 weeks of gestation or earlier when there is a maternal history of recurrent miscarriage (defined as a history of ≥ 2 failed pregnancies); **OR**
- In all cases of pregnancy loss after 20 weeks of gestation.

Policy Guidelines

Clinical guidelines and recommendations to address the management of cases of miscarriage or intrauterine fetal demise where genetic analysis of the embryo, fetus, or stillborn infant is indicated. These guidelines, which specifically address the use of karyotyping and/or microarray testing in miscarriage or intrauterine fetal demise, were developed by reproductive health associations, including the American Society for Reproductive Medicine and the American College of Obstetricians and Gynecologists. The decision to obtain genetic testing should be made jointly between the mother or parents and the treating clinician.

This policy does not address the use of chromosomal microarray analysis (CMA) testing for preimplantation genetic diagnosis or preimplantation genetic screening, or the evaluation of suspected chromosomal abnormalities in the postnatal period.

GENETIC COUNSELING

Genetic counseling is primarily aimed at patients who are at risk for inherited disorders, and experts recommend formal genetic counseling in most cases when genetic testing for an inherited condition is considered. The interpretation of the results of genetic tests and the

MEDICAL POLICY

POLICY TITLE	CHROMOSOMAL MICROARRAY TESTING FOR THE EVALUATION OF PREGNANCY LOSS
POLICY NUMBER	MP 7.028

understanding of risk factors can be very difficult and complex. Therefore, genetic counseling will assist individuals in understanding the possible benefits and harms of genetic testing, including the possible impact of the information on the individual's family. Genetic counseling may alter the utilization of genetic testing substantially and may reduce inappropriate testing. Genetic counseling should be performed by an individual with experience and expertise in genetic medicine and genetic testing methods.

Cross-reference:

MP 2.242 Genetic Testing for Developmental Delay-Intellectual Disability, Autism Spectrum Disorder, and Congenital Anomalies
MP 7.009 Preimplantation Genetic Testing

II. PRODUCT VARIATIONS

[TOP](#)

This policy is only applicable to certain programs and products administered by Capital Blue Cross and subject to benefit variations as discussed in Section VI. Please see additional information below.

FEP PPO - Refer to FEP Medical Policy Manual. The FEP Medical Policy manual can be found at: <https://www.fepblue.org/benefit-plans/medical-policies-and-utilization-management-guidelines/medical-policies>

III. DESCRIPTION/BACKGROUND

[TOP](#)

PREGNANCY LOSS: ETIOLOGY AND EVALUATION

Early Pregnancy Loss

Pregnancy loss is common, occurring in at least 15% to 25% of recognized pregnancies. Most pregnancy loss occurs early in the pregnancy, most often by the end of the first trimester or early second trimester. Pregnancy loss that occurs before the 20th week of gestation is referred to as a spontaneous abortion, early pregnancy loss, or miscarriage. While a wide range of factors can lead to early pregnancy loss, genetic causes are thought to be the predominant cause: when products of conception (POC) are examined, it is estimated that 60% of early pregnancy losses are associated with chromosomal abnormalities, particularly trisomies and monosomy X. The increasing risk of trisomies with maternal age contributes to the increased risk of early pregnancy loss with increasing maternal age.

Recurrent pregnancy loss, defined by the American Society for Reproductive Medicine (ASRM) as 2 or more failed pregnancies, is less common, occurring in approximately 5% of women. Recurrent pregnancy loss may be related to cytogenetic abnormalities, particularly balanced translocations, uterine abnormalities, thrombophilias, including antiphospholipid syndrome, and metabolic or endocrinologic disorders such as uncontrolled diabetes and thyroid disease. Estimates for the frequency of various underlying causes of recurrent pregnancy loss vary widely, with ranges from 2% to 6% for cytogenetic abnormalities, 8% to 42% for

MEDICAL POLICY

POLICY TITLE	CHROMOSOMAL MICROARRAY TESTING FOR THE EVALUATION OF PREGNANCY LOSS
POLICY NUMBER	MP 7.028

antiphospholipid antibody syndrome, and 1.8% to 37.6% for uterine abnormalities. It is likely that the risk of cytogenetic abnormalities is lower in recurrent early pregnancy loss than in isolated spontaneous early pregnancy loss.

Clinicians and patients may evaluate for the cause of a single or recurrent early pregnancy loss for several reasons. The knowledge that an early pregnancy loss is secondary to a sporadic genetic abnormality may provide parents with reassurance that there was nothing that they did or did not do that contributed to the loss, although the magnitude of this benefit is difficult to quantify. For couples with recurrent pregnancy loss and evidence of a structural genetic abnormality in one of the parents, preimplantation genetic diagnosis with transfer of unaffected embryos or the use of donor gametes might be considered for therapy. These therapies might be considered for couples with recurrent pregnancy loss without evidence of a structural genetic abnormality in one of the parents; 2012 guidelines on the management of recurrent pregnancy loss from ASRM have indicated that “treatment options should be based on whether repeated miscarriages are euploid, aneuploidy, or due to an unbalanced structural rearrangement and not exclusively on the parental carrier status.” Finally, among patients found to have a potential *nongenetic* underlying cause of recurrent pregnancy loss, such as antiphospholipid syndrome, cytogenetic analysis of pregnancy losses could provide evidence that the miscarriages were not due to treatment failure.

Late Pregnancy Loss

Fetal loss that occurs later in pregnancy, after 20 weeks of gestation, may be referred to as intrauterine fetal demise (IUFD), stillbirth, or intrauterine fetal death. In 2013, IUFD occurred in 5.96 of 1000 births in the United States, representing about 60% of perinatal mortality. In many cases, the precise cause of IUFD is unidentifiable; however, it may be related to a range of disorders, including genetic disorders in the fetus, maternal infection, coexisting maternal medical disorders (e.g., diabetes, antiphospholipid antibody syndrome, heritable thrombophilias), and obstetric complications. Chromosomal or genetic abnormalities can be found in 8% to 13% of IUFD—most commonly aneuploidies. In a large 2012 series of IUFD (N=1025), cytogenetic abnormalities were detected in 11.9%.

Reasons for evaluation for a cause of IUFD are similar to those for earlier pregnancy loss. Although both early and later pregnancy losses may cause grief for the mother and her family, IUFD can be particularly devastating. Information about the cause of the pregnancy loss may be important in counseling women about their recurrence risk. In low-risk women with an unexplained IUFD, the risk of recurrence is 7.8 to 10.5 of 1000 live births, but this increases to 21.8 per 1000 live births in women with a history of fetal growth restriction. Identification of a heritable genetic variant in a fetus may prompt testing in the parents; if a heritable variant is identified, parents may pursue preimplantation genetic diagnosis in future pregnancies.

CHROMOSOMAL MICROARRAY TESTING

There is interest in using alternative genetic testing methods, particularly array comparative genomic hybridization (aCGH), to detect chromosomal or other genetic abnormalities in the evaluation of miscarriages and IUFD.

MEDICAL POLICY

POLICY TITLE	CHROMOSOMAL MICROARRAY TESTING FOR THE EVALUATION OF PREGNANCY LOSS
POLICY NUMBER	MP 7.028

REGULATORY STATUS

Clinical laboratories may develop and validate tests in-house and market them as a laboratory service; laboratory-developed tests must meet the general regulatory standards of the Clinical Laboratory Improvement Act. Laboratories that offer laboratory-developed tests must be licensed by the Clinical Laboratory Improvement Act for high-complexity testing. To date, the U.S. Food and Drug Administration has chosen not to require any regulatory review of this test.

Multiple laboratories offer chromosomal microarray tests for prenatal samples that are not specifically designed for testing the products of conception.

IV. RATIONALE

[TOP](#)

SUMMARY OF EVIDENCE

For individuals who have pregnancy loss with indications for genetic analysis of the embryo or fetus who receive CMA testing of fetal tissue, the evidence includes prospective and retrospective cohort studies that report on the yield of CMA testing. Relevant outcomes are test accuracy and validity, other test performance measures, changes in reproductive decision making, morbid events, and quality of life. The available evidence has suggested that CMA testing has a high rate of concordance with standard karyotyping. For both early and late pregnancy loss, CMA is more likely to yield a result than karyotyping. Other studies have reported that CMA testing detects a substantial number of abnormalities in patients with normal karyotypes, although the precise yield is uncertain and likely varies based on gestational age. Rates of variants of uncertain significance in CMA testing of miscarriage samples are not well characterized. Potential benefits from identifying a genetic abnormality in a miscarriage or IUFD include reducing emotional distress for families, altering additional testing undertaken to assess for other causes of pregnancy loss, and changing reproductive decision making for future pregnancies. The potential for clinical utility with CMA testing of fetal tissue in pregnancy loss is parallel to that for obtaining a karyotype of fetal tissue in pregnancy loss, which is recommended by a number of organizations. None of the studies identified directly demonstrated whether (or how) patient management would change based on CMA testing of POC from early or late pregnancy losses, nor did they demonstrate how patient outcomes would improve; however, the available evidence suggests that, for situations in which a genetic evaluation is indicated, CMA testing would be expected to perform as well as (or better) than standard karyotyping. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

V. DEFINITIONS

[TOP](#)

Early pregnancy loss or miscarriage is considered to be a pregnancy loss that occurs at or before 20 weeks of gestational age.

Fetal tissue may consist of fetal tissue, a formed fetus, or placental tissue derived from the fetal genotype, depending on the stage of pregnancy at the time of the fetal loss.

MEDICAL POLICY

POLICY TITLE	CHROMOSOMAL MICROARRAY TESTING FOR THE EVALUATION OF PREGNANCY LOSS
POLICY NUMBER	MP 7.028

Intrauterine fetal demise is defined as delivery of a non-live-born fetus after 20 weeks of gestational age.

VI. BENEFIT VARIATIONS

[TOP](#)

The existence of this medical policy does not mean that this service is a covered benefit under the member's health benefit plan. Benefit determinations should be based in all cases on the applicable health benefit plan language. Medical policies do not constitute a description of benefits. A member's health benefit plan governs which services are covered, which are excluded, which are subject to benefit limits, and which require preauthorization. There are different benefit plan designs in each product administered by Capital Blue Cross. Members and providers should consult the member's health benefit plan for information or contact Capital Blue Cross for benefit information.

VII. DISCLAIMER

[TOP](#)

Capital Blue Cross' medical policies are developed to assist in administering a member's benefits, do not constitute medical advice and are subject to change. Treating providers are solely responsible for medical advice and treatment of members. Members should discuss any medical policy related to their coverage or condition with their provider and consult their benefit information to determine if the service is covered. If there is a discrepancy between this medical policy and a member's benefit information, the benefit information will govern. If a provider or a member has a question concerning the application of this medical policy to a specific member's plan of benefits, please contact Capital Blue Cross' Provider Services or Member Services. Capital Blue Cross considers the information contained in this medical policy to be proprietary and it may only be disseminated as permitted by law.

VIII. CODING INFORMATION

[TOP](#)

Note: This list of codes may not be all-inclusive, and codes are subject to change at any time. The identification of a code in this section does not denote coverage as coverage is determined by the terms of member benefit information. In addition, not all covered services are eligible for separate reimbursement.

Covered when medically necessary:

Procedure Codes								
81228	81229	81479	0252U					

MEDICAL POLICY

POLICY TITLE	CHROMOSOMAL MICROARRAY TESTING FOR THE EVALUATION OF PREGNANCY LOSS
POLICY NUMBER	MP 7.028

ICD-10-CM Diagnosis Codes	Description
N96	Recurrent pregnancy loss
O02.1	Missed abortion
O02.9	Abnormal product of conception, unspecified
O03.4	Incomplete spontaneous abortion without complication
O03.89	Complete or unspecified spontaneous abortion with other complications
O03.9	Complete or unspecified spontaneous abortion without complication
O26.20	Pregnancy care for patient with recurrent pregnancy loss, unspecified trimester
O26.21	Pregnancy care for patient with recurrent pregnancy loss, first trimester
O26.22	Pregnancy care for patient with recurrent pregnancy loss, second trimester
O26.23	Pregnancy care for patient with recurrent pregnancy loss, third trimester
O36.4XX0	Maternal care for intrauterine death, not applicable or unspecified
O36.4XX1	Maternal care for intrauterine death, fetus 1
O36.4XX2	Maternal care for intrauterine death, fetus 2
O36.4XX3	Maternal care for intrauterine death, fetus 3
O36.4XX4	Maternal care for intrauterine death, fetus 4
O36.4XX5	Maternal care for intrauterine death, fetus 5
O36.4XX9	Maternal care for intrauterine death, other fetus
Z37.1	Single stillbirth
Z37.3	Twins, one liveborn and one stillborn
Z37.4	Twins, both stillborn
Z37.60	Multiple births, unspecified, some liveborn
Z37.61	Triplets, some liveborn
Z37.62	Quadruplets, some liveborn
Z37.63	Quintuplets, some liveborn
Z37.64	Sextuplets, some liveborn
Z37.69	Other multiple births, some liveborn
Z37.7	Other multiple births, all stillborn

MEDICAL POLICY

POLICY TITLE	CHROMOSOMAL MICROARRAY TESTING FOR THE EVALUATION OF PREGNANCY LOSS
POLICY NUMBER	MP 7.028

IX. REFERENCES

[TOP](#)

1. Pfeifer S, Fritz M, Goldberg J, et al. Evaluation and treatment of recurrent pregnancy loss: a committee opinion. *Fertil Steril*. Nov 2012; 98(5): 1103-11. PMID 22835448
2. Laurino MY, Bennett RL, Saraiya DS, et al. Genetic evaluation and counseling of couples with recurrent miscarriage: recommendations of the National Society of Genetic Counselors. *J Genet Couns*. Jun 2005; 14(3): 165-81. PMID 15959648
3. Practice Committee of the American Society for Reproductive Medicine. Electronic address: asrm@asrm.org. Definitions of infertility and recurrent pregnancy loss: a committee opinion. *Fertil Steril*. Mar 2020; 113(3): 533-535. PMID 32115183
4. Practice Committee of the American Society for Reproductive Medicine. Definitions of infertility and recurrent pregnancy loss: a committee opinion. *Fertil Steril*. Jan 2013; 99(1): 63. PMID 23095139
5. Christiansen OB. Evidence-based investigations and treatments of recurrent pregnancy loss. *Curr Opin Obstet Gynecol*. Jun 2006; 18(3): 304-12. PMID 16735831
6. Management of Stillbirth: Obstetric Care Consensus No. 10. *Obstet Gynecol*. Mar 2020; 135(3): e110-e132. PMID 32080052
7. Korteweg FJ, Erwich JJ, Timmer A, et al. Evaluation of 1025 fetal deaths: proposed diagnostic workup. *Am J Obstet Gynecol*. Jan 2012; 206(1): 53.e1-53.e12. PMID 22196684
8. Robberecht C, Schuddinck V, Fryns JP, et al. Diagnosis of miscarriages by molecular karyotyping: benefits and pitfalls. *Genet Med*. Sep 2009; 11(9): 646-54. PMID 19617844
9. Kearney HM, Thorland EC, Brown KK, et al. American College of Medical Genetics standards and guidelines for interpretation and reporting of postnatal constitutional copy number variants. *Genet Med*. Jul 2011; 13(7): 680-5. PMID 21681106
10. Riggs ER, Andersen EF, Cherry AM, et al. Technical standards for the interpretation and reporting of constitutional copy-number variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics (ACMG) and the Clinical Genome Resource (ClinGen). *Genet Med*. Feb 2020; 22(2): 245-257. PMID 31690835
11. Martinez-Portilla RJ, Pauta M, Hawkins-Villarreal A, et al. Added value of chromosomal microarray analysis over conventional karyotyping in stillbirth work-up: systematic review and meta-analysis. *Ultrasound Obstet Gynecol*. May 2019; 53(5): 590-597. PMID 30549343
12. Dhillon RK, Hillman SC, Morris RK, et al. Additional information from chromosomal microarray analysis (CMA) over conventional karyotyping when diagnosing chromosomal abnormalities in miscarriage: a systematic review and meta-analysis. *BJOG*. Jan 2014; 121(1): 11-21. PMID 23859082
13. Lee JM, Shin SY, Kim GW, et al. Optimizing the Diagnostic Strategy to Identify Genetic Abnormalities in Miscarriage. *Mol Diagn Ther*. May 2021; 25(3): 351-359. PMID 33792848
14. Schilit SLP, Studwell C, Flatley P, et al. Chromosomal microarray analysis in pregnancy loss: Is it time for a consensus approach?. *Prenat Diagn*. Nov 2022; 42(12): 1545-1553. PMID 36176068

MEDICAL POLICY

POLICY TITLE	CHROMOSOMAL MICROARRAY TESTING FOR THE EVALUATION OF PREGNANCY LOSS
POLICY NUMBER	MP 7.028

15. Lathi RB, Massie JA, Loring M, et al. Informatics enhanced SNP microarray analysis of 30 miscarriage samples compared to routine cytogenetics. *PLoS One*. 2012; 7(3): e31282. PMID 22403611
16. Menten B, Swerts K, Delle Chiaie B, et al. Array comparative genomic hybridization and flow cytometry analysis of spontaneous abortions and mors in utero samples. *BMC Med Genet*. Sep 14 2009; 10: 89. PMID 19751515
17. Hu Y, Chen X, Chen LL, et al. Comparative genomic hybridization analysis of spontaneous abortion. *Int J Gynaecol Obstet*. Jan 2006; 92(1): 52-7. PMID 16263126
18. Lathi RB, Gustin SL, Keller J, et al. Reliability of 46,XX results on miscarriage specimens: a review of 1,222 first-trimester miscarriage specimens. *Fertil Steril*. Jan 2014; 101(1): 178-82. PMID 24182409
19. Viaggi CD, Cavani S, Malacarne M, et al. First-trimester euploid miscarriages analysed by array-CGH. *J Appl Genet*. Aug 2013; 54(3): 353-9. PMID 23780398
20. Centre for Applied Genomics. Database of Genomic Variants. n.d.; Accessed June 14, 2023.
21. Wellcome Trust Sanger Institute. DECIPHER GRCh37. Version 11.12. 2022; Accessed June 14, 2023.
22. Dória S, Carvalho F, Ramalho C, et al. An efficient protocol for the detection of chromosomal abnormalities in spontaneous miscarriages or foetal deaths. *Eur J Obstet Gynecol Reprod Biol*. Dec 2009; 147(2): 144-50. PMID 19740589
23. Benkhalifa M, Kasakyan S, Clement P, et al. Array comparative genomic hybridization profiling of first-trimester spontaneous abortions that fail to grow in vitro. *Prenat Diagn*. Oct 2005; 25(10): 894-900. PMID 16088865
24. Maslow BS, Budinetz T, Sueldo C, et al. Single-Nucleotide Polymorphism-Microarray Ploidy Analysis of Paraffin-Embedded Products of Conception in Recurrent Pregnancy Loss Evaluations. *Obstet Gynecol*. Jul 2015; 126(1): 175-81. PMID 26241271
25. Romero ST, Geiersbach KB, Paxton CN, et al. Differentiation of genetic abnormalities in early pregnancy loss. *Ultrasound Obstet Gynecol*. Jan 2015; 45(1): 89-94. PMID 25358469
26. Levy B, Sigurjonsson S, Pettersen B, et al. Genomic imbalance in products of conception: single-nucleotide polymorphism chromosomal microarray analysis. *Obstet Gynecol*. Aug 2014; 124(2 Pt 1): 202-209. PMID 25004334
27. Mathur N, Triplett L, Stephenson MD. Miscarriage chromosome testing: utility of comparative genomic hybridization with reflex microsatellite analysis in preserved miscarriage tissue. *Fertil Steril*. May 2014; 101(5): 1349-52. PMID 24636399
28. Warren JE, Turok DK, Maxwell TM, et al. Array comparative genomic hybridization for genetic evaluation of fetal loss between 10 and 20 weeks of gestation. *Obstet Gynecol*. Nov 2009; 114(5): 1093-1102. PMID 20168112
29. Sahlin E, Gustavsson P, Liedén A, et al. Molecular and cytogenetic analysis in stillbirth: results from 481 consecutive cases. *Fetal Diagn Ther*. 2014; 36(4): 326-32. PMID 25059832
30. Reddy UM, Page GP, Saade GR, et al. Karyotype versus microarray testing for genetic abnormalities after stillbirth. *N Engl J Med*. Dec 06 2012; 367(23): 2185-93. PMID 23215556

MEDICAL POLICY

POLICY TITLE	CHROMOSOMAL MICROARRAY TESTING FOR THE EVALUATION OF PREGNANCY LOSS
POLICY NUMBER	MP 7.028

31. Harris RA, Ferrari F, Ben-Shachar S, et al. Genome-wide array-based copy number profiling in human placentas from unexplained stillbirths. *Prenat Diagn.* Oct 2011; 31(10): 932-44. PMID 21732394
32. Raca G, Artzer A, Thorson L, et al. Array-based comparative genomic hybridization (aCGH) in the genetic evaluation of stillbirth. *Am J Med Genet A.* Nov 2009; 149A(11): 2437-43. PMID 19876905
33. Bernardi LA, Plunkett BA, Stephenson MD. Is chromosome testing of the second miscarriage cost saving? A decision analysis of selective versus universal recurrent pregnancy loss evaluation. *Fertil Steril.* Jul 2012; 98(1): 156-61. PMID 22516510
34. Vora NL, Romero ST, Ralston SJ, et al. Committee Opinion No.682: Microarrays and Next-Generation Sequencing Technology: The Use of Advanced Genetic Diagnostic Tools in Obstetrics and Gynecology. *Obstet Gynecol.* Dec 2016; 128(6): e262-e268. PMID 27875474
35. Blue Cross Blue Shield Association Medical Policy Reference Manual. 2.04.122, Chromosomal Microarray Testing for the Evaluation of Early Pregnancy Loss. August 2024

X. POLICY HISTORY

[Top](#)

MP 7.028	03/06/2020 Consensus Review. FEP Policy no longer effective. References reviewed.
	06/15/2021 Administrative Update. Added new code 0252U.
	10/28/2021 Consensus Review. No change to policy statement. FEP language updated.
	11/18/2022 Consensus Review. No change to policy statement. Background, references updated. No coding changes.
	12/20/2023 Consensus Review. No change to policy statement. Code 88262 removed from policy. Reference and guidelines updated.
	08/20/2024 Minor Review. Updated the policy statement. References updated. Updated coding table.

[Top](#)

Health care benefit programs issued or administered by Capital Blue Cross and/or its subsidiaries, Capital Advantage Insurance Company®, Capital Advantage Assurance Company® and Keystone Health Plan® Central. Independent licensees of the BlueCross BlueShield Association. Communications issued by Capital Blue Cross in its capacity as administrator of programs and provider relations for all companies.